Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: EGFR Mutated Non-small Cell Lung Cancer Patients Clear all
Recruiting Phase 1 Interventional

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT05681780
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy, Interleukin-2 (IL2)
Biological · Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 2 Interventional

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions
Sterotactic Body Radiotherapy/SBRT, Standard of care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Completed Phase 1 Interventional

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC

NCT04959981
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer
Interventions
ERAS-007, ERAS-601, Osimertinib, Sotorasib
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Duarte, California • Orange, California • Santa Monica, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 1, 2026, 9:59 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Newport Beach, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

NCT03944265
View directory record Official record
Conditions
Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative, Health Care Provider, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Counseling, Questionnaire Administration, Medical Chart Review
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 2 Interventional

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448
View directory record Official record
Conditions
Lung Cancer
Interventions
Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
La Jolla, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 1 Interventional

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

NCT05166616
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Biopsy, Osimertinib, Triptolide Analog
Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

NCT00997334
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Erlotinib
Drug
Lead sponsor
David M. Jackman, MD
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 1, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

NCT02485652
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
HM61713
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
20 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
15
States / cities
Beverly Hills, California • Burbank, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
12
States / cities
Duarte, California • Irvine, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

NCT02323126
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
EGF816, INC280, Nivolumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Silver Spring, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

NCT03455829
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-small Cell Lung Cancer
Interventions
G1T38, Osimertinib
Drug
Lead sponsor
G1 Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
8
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 1, 2026, 9:59 PM EDT
Approved For Marketing No phase listed Expanded access

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

NCT06279728
View directory record Official record
Conditions
EGFRm Advanced Non-Small Cell Lung Cancer, EGFRm Metastatic Non-Small Cell Lung Cancer
Interventions
Datopotamab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
U.S. locations
14
States / cities
Springdale, Arkansas • Honolulu, Hawaii • Bowling Green, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04743505
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
APL-101, Osimertinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 2 Interventional

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Completed Phase 4 Interventional Results available

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

NCT02514174
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, ErbB Receptors
Interventions
Afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
70 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Anaheim, California • Duarte, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 1, 2026, 9:59 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

NCT06868485
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level B
Drug
Lead sponsor
Wayshine Biopharm, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Oxnard, California • Weston, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 1, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

NCT04862780
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, Neoplasms, Nerve Tissue, EGFR T790M, EGFR C797S, EGFR L858R, EGFR Gene Mutation, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Exon 19 Deletion, EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance, EGFR Activating Mutation, Protein Kinase Inhibitors, Antineoplastic Agents, Thoracic Neoplasms
Interventions
BLU-945, osimertinib
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 1, 2026, 9:59 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients

NCT06659458
View directory record Official record
Conditions
Lung Cancer - Non Small Cell, EGFR Exon 19 Deletion Mutation
Interventions
blood draw, Gene sequencing
Other
Lead sponsor
Our Lady of the Lake Hospital
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 1, 2026, 9:59 PM EDT
Terminated Phase 1 Interventional

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Afatinib, Necitumumab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Duarte, California • Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 1, 2026, 9:59 PM EDT
Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501
View directory record Official record
Conditions
NSCLC
Interventions
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
EQRx International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 1, 2026, 9:59 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102
View directory record Official record
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Standard of Care, Telisotuzumab Adizutecan, Osimertinib (Osi), Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
14
States / cities
Chandler, Arizona • Los Angeles, California • Newport Beach, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 1, 2026, 9:59 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

NCT04035486
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
23
States / cities
Bellflower, California • Fullerton, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 1, 2026, 9:59 PM EDT